Cystoid macular edema in uveitis

Ocular Immunology and Inflammation

Volumn 11, Issue 1, 2003, Pages 29-38

  Okhravi, Narciss ^a   Lightman, Susan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Cystoid; Edema; Macular; Steroids; Uveitis

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CYCLOSPORIN; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; TRIAMCINOLONE;

ARTICLE; BLINDNESS; CATARACT EXTRACTION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; HUMAN; HYPERTENSION; INFLAMMATION; IRIDOCYCLITIS; MENTAL DISEASE; PATHOGENESIS; PERFORATING EYE INJURY; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINITIS; STEROID THERAPY; STOMACH ULCER; UVEITIS; VISUAL IMPAIRMENT; VITRECTOMY;

HUMANS; MACULAR EDEMA, CYSTOID; UVEITIS;

EID: 0043167820     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.1076/ocii.11.1.29.15582     Document Type: Article

References (40)

1. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332-336.
2. Atmaca LS. Fundus changes associated with Behcet's disease. Graefes Arch Clin Exp Ophthalmol. 1989;227:340-344.
3. Prieto JF, Dios E, Gutierrez JM, Mayo A, Calonge M, Herreras JM. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm. 2001;9:93-102.
4. Henderly DE, Genstler AJ, Rao NA, Smith RE. Pars planitis. Trans Ophthalmol Soc UK. 1986;105:227-232.
5. Henderly DE, Haymond RS, Rao NA, Smith RE. The significance of the pars plana exudate in pars planitis. Am J Ophthalmol. 1987;103:669-671.
6. Yanoff M, Fine BS, Brucker AJ, Eagle Jr RC. Pathology of human cystoid macular edema. Surv Ophthalmol. 1984;28(Suppl):501-511.
7. Hirokawa H, Takahashi M, Trempe CL. Vitreous changes in peripheral uveitis. Arch Ophthalmol. 1985;103:1704-1707.
8. Hikichi T, Trempe CL. Role of the vitreous in the prognosis of peripheral uveitis. Am J Ophthalmol. 1993;116:401-405.
9. Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine, 1992;4:1-5.
10. Lightman S, Chan CC. Immune mechanisms in choroido-retinal inflammation in man. Eye. 1990;4:345-353.
11. Lightman S, Greenwood J. Effect of lymphocytic infiltration on the blood-retinal barrier in experimental autoimmune uveoretinitis. Clin Exp Immunol. 1992;88:473-477.
12. Lightman SL, Caspers-Velu LE, Hirose S, Nussenblatt RB, Palestine AG. Angiography with fluorescein-labeled dextrans in a primate model of uveitis. Arch Ophthalmol. 1987;105:844-848.
13. Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol. 1999;97:297-309.
14. Lightman S. Use of steroids and immunosuppressive drugs in the management of posterior uveitis. Eye. 1991;5:294-298.
15. rd FL. Macular thickening and visual acuity. Measurement in patients with cystoid macular edema. Ophthalmology. 1987;94:1134-1139.
16. McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis. Br Med J. 2000;320:555-558.
17. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
18. Rojas B, Zafirakis P, Christen W, Markomichelakis NN, Foster CS. Medical treatment of macular edema in patients with uveitis. Doc Ophthalmol. 1999;97:399-407.
19. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol. 2001;29:2-6.
20. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999;106:370-374.
21. Goldstein DA, Fontanilla FA, Kaul S, Sahin O, Tessler HH. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109:370-377.
22. Herbort CP, Okumura A, Mochizuki M. Immunopharmacological analysis of endotoxin-induced uveitis in the rat. Exp Eye Res. 1989;48:693-705.
23. Mishima H, Masuda K, Miyake K. The putative role of prostaglandins in cystoid macular edema. Prog Clin Biol Res. 1989;312:251-264.
24. Goa KL, Chrisp P. Ocular diclofenac. A review of its pharmacology and clinical use in cataract surgery, and potential in other inflammatory ocular conditions. Drugs Aging. 1992;2:473-486.
25. Dugel PU, Rao NA, Ozler S, Liggett PE, Smith RE. Pars plana vitrectomy for intraocular inflammation-related cystoid macular edema unresponsive to corticosteroids. A preliminary study. Ophthalmology. 1992;99:1535-1541.
26. Aylward GW. The place of vitreoretinal surgery in the treatment of macular oedema. Doc Ophthalmol. 1999;97:433-438.
27. Verbraeken H. Pars plana lensectomy in cases of cataract with juvenile chronic uveitis. Graefes Arch Clin Exp Ophthalmol. 1996;234:618-622.
28. Okhravi N, Towler HM, Lightman SL. Cataract surgery in patients with uveitis. Eye. 2000;14(5):689-690.
29. Smith JR. Management of uveitis in pediatric patients: special considerations. Paediatr Drugs. 2002;4:183-189.
30. Guest S, Funkhouser E, Lightman S. Pars planitis: a comparison of childhood onset and adult onset disease. Clin Exp Ophthalmol. 2001;29:81-84.
31. Karavellas MP, Azen SP, MacDonald JC, Shufelt CL, Lowder CY, Plummer DJ, Glasgow B, Torriani FJ, Freeman WR. Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequlae, and treatment outcomes. Retina. 2001;21:1-9.
32. Lightman S, Kok H. Developments in the treatment of uveitis. Expert Opin Invest Drugs. 2002;11:59-67.
33. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust NZ J Ophthalmol. 1995;23:293-298.
34. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Exp Ophthalmol. 2001;29:188-192.
35. Enyedi LB, Pearson PA, Ashton P, Jaffe GJ. An intravitreal device providing sustained release of cyclosporine and dexamethasone. Curr Eye Res. 1996;15:549-557.
36. Jaffe GJ, Yang CS, Wangm XC, Cousins W, Gallemore RP, Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998;105:46-56.
37. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024-2033.
38. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 2000;20:402-403.
39. Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001;132:794-796.
40. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.